Defining Zoledronate’s Duration of Action and Optimal Dosing Interval for an Effective Therapy
- Stuart L. Silverman
- … show all 1 hide
Grey A, Boland M, Wattie D, et al.: Prolonged antiresorptive activity of zoledronate: a randomized control trial. Gen Bone Miner Res 2010, 25:2251–2255.
Zoledronic acid (ZA) is a potent nitrogen-containing bisphosphonate with a long skeletal half-life that is administered annually by intravenous (IV) infusion. In the Horizon trial, ZA significantly reduced the risk of vertebral fracture by 70%, the risk of hip fracture by 40%, and the risk of nonvertebral fracture by 20% . ZA also reduced the risk of clinical fracture by 35% and decreased mortality by 28% after hip fracture in the Recurrent Fracture Trial . A combination of antifracture efficacy, low rate of adverse events, and infrequent dosing make it a desirable agent for the future.
Defining the duration of action of zoledronate and the optimal dosing interval may help reduce the cost of an effective therapy.
Andrew Grey performed a 3-year randomized placebo-controlled trial of the effects on bone tur
- Black DM, Delmas PD, Eastell R, et al.: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007 May 3;356(18):1809–22. CrossRef
- Lyles KW, Colón-Emeric CS, Magaziner JS, et al.: Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. N Engl J Med. 2007;357:nihpa40967.
- Black DM, et al: The effect of 3 versus 6 years of Zoledronic acid treatment in osteoporosis: a randomized extension to the Horizon Pivotal Fracture Trial. Presented at the American Society for Bone and Mineral Research 2010 Annual Meeting. Toronto, Canada; October 15–19, 2010.
- Defining Zoledronate’s Duration of Action and Optimal Dosing Interval for an Effective Therapy
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Current Osteoporosis Reports
Volume 9, Issue 1 , pp 4-5
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Author Affiliations
- 1. Medical Director Cedars-Sinai Bone Center of Excellence, David Geffen School of Medicine UCLA, 8641 Wilshire Boulevard, Suite 301, Beverly Hills, CA, 90211, USA